Daiken Biomedical Co., Ltd. (7780) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Daiken Biomedical Co., Ltd. stock TWD 15.90, price TWD 14.50, upside +9.6%, quality 57 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
24‑month range 13.54 TWD – 180.45 TWD · fair‑value band 11.43 TWD – 22.87 TWD · the 14.50 TWD price screens below the 15.90 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Daiken Biomedical Co. in your weekly email
Every Wednesday you see whether Daiken Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company was founded in 2018 and is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd. operates as a subsidiary of Sunfun Info Co., Ltd.
Stock analysis
Daiken Biomedical Co., Ltd. (7780) currently trades at 14.50 TWD, while our model-based Fair Value estimate is 15.90 TWD, so the stock looks roughly fairly valued today (gap 8.8%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 17.87 TWD per share, and 5 of the 26 models we run sit above the 14.50 TWD price.
Bear case: the Economic Profit group reads lowest at 5.14 TWD, and 21 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 11.43 TWD (bear) to 22.87 TWD (bull), the price of 14.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Daiken Biomedical Co., Ltd. reported revenue of 1.9B TWD in FY2025 versus 885M TWD in FY2022, a compound +28.9%/yr. Reported net income was 338M TWD in FY2025, compounding +55.3%/yr from FY2022.
Key figures
Market cap 11.7B TWD (≈ $358M) Small · P/E ratio 145.0 · P/S ratio 25.9 · EPS (TTM) 0.1000 TWD · Dividend yield 3.4% · Net margin 17.8% · Return on equity 14.2% · Return on assets (EBIT) 15.8% (4-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 92% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 10%, 7780 screens cheaper than that median.
Fair Value models
Bear11.43 TWDFair Value 15.90 TWDBull22.87 TWD
Price 14.50 TWD · Upside +9.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+39.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.9%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +13.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.5%
Dividend (yield on the price)3.4%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 15%
⚠ Rate on operating basis: 2025 sits 56% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +24.1% a year for the price.
Compare Daiken Biomedical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+9.6% · Above median
Profitability
Return on equity (12 months)14.2% · Top 25%
Return on assets5.7% · Above median
Net margin (12 months)19.4% · Top 25%
Operating margin (12 months)20.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)35.5% · Top 25%
Dividend yield (12 months)3.4% · Above median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Daiken Biomedical Co., Ltd. (7780) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 15.90 TWD versus a price of 14.50 TWD, about +10% upside (fairly valued).
What is the fair value of 7780?
Our model-based fair value for Daiken Biomedical Co., Ltd. is 15.90 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 14.50 TWD.
What is the quality score of 7780?
Daiken Biomedical Co., Ltd. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daiken Biomedical Co., Ltd. (7780)?
Our model-based price target is the fair value of 15.90 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 11.43 TWD, optimistic scenario 22.87 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Daiken Biomedical Co., Ltd. stock forecast for 2026?
Our models put fair value at 15.90 TWD, about +10% upside versus a price of 14.50 TWD (fairly valued). Cautious scenario 11.43 TWD, optimistic scenario 22.87 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Daiken Biomedical Co., Ltd. (7780)?
Daiken Biomedical Co., Ltd. reported trailing-twelve-month revenue of about 2.2B TWD (latest available figure, as of Nov 8, 2026).
Does Daiken Biomedical Co., Ltd. pay a dividend?
Daiken Biomedical Co., Ltd. currently shows a dividend yield of 3.41% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Daiken Biomedical Co., Ltd. (7780) and when is the ex-dividend date?
Daiken Biomedical Co., Ltd. pays a dividend of 0.495 TWD per share a year, a dividend yield of 3.4%. The last ex-dividend date was Sep 3, 2026. Free cash flow covers the dividend 0.67 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into Daiken Biomedical Co., Ltd. (7780)?
For today's price to be fair in a discounted-cash-flow model, Daiken Biomedical Co., Ltd. would have to grow free cash flow by +26.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +28.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 7780 use?
Our models discount Daiken Biomedical Co., Ltd. at 11.8 %: a base by market capitalisation (small), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daiken Biomedical Co., Ltd. that is +26.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Daiken Biomedical Co., Ltd. (7780) delivered so far?
Over the past 3 years revenue at Daiken Biomedical Co., Ltd. grew +28.9 % a year. The price currently implies free-cash-flow growth of +26.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daiken Biomedical Co., Ltd. (7780) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into Daiken Biomedical Co., Ltd. (+26.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daiken Biomedical Co., Ltd. (7780)?
The free-cash-flow yield on the price is 2.29 %: that much free cash flow Daiken Biomedical Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daiken Biomedical Co., Ltd. (7780)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daiken Biomedical Co., Ltd. it is 15.90 TWD per share (as of Nov 8, 2026), against a price of 14.50 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Daiken Biomedical Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 7780 trades below its calculated fair value: price 14.50 TWD, fair value 15.90 TWD, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7780?
No. The price is what the market pays today (14.50 TWD); the fair value is what the company's own numbers justify (15.90 TWD). For Daiken Biomedical Co., Ltd. the two are 1.40 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Daiken Biomedical Co., Ltd. worth?
The market values Daiken Biomedical Co., Ltd. at about 11.7B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 14.50 TWD; our models calculate a fair value of 15.90 TWD per share.
What do the bullish and bearish scenarios say about 7780?
Our models span a range for Daiken Biomedical Co., Ltd.: cautious scenario 11.43 TWD, base 15.90 TWD, optimistic 22.87 TWD per share (as of Nov 8, 2026, price 14.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7780?
Daiken Biomedical Co., Ltd. trades at a price-to-earnings ratio of 145.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 15.90 TWD is built from several models across several years.
How solid is the balance sheet of Daiken Biomedical Co., Ltd. (7780)?
Balance-sheet figures for Daiken Biomedical Co., Ltd. (as of Nov 8, 2026): return on equity 14.2%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 7780 from its 52-week high?
Daiken Biomedical Co., Ltd. trades at 14.50 TWD, about 92% below its 52-week high of 180.45 TWD and at the low of 14.45 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 15.90 TWD is for.
Which stocks are comparable to Daiken Biomedical Co., Ltd.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daiken Biomedical Co., Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price 14.50 TWD, calculated fair value 15.90 TWD (+10%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7780 calculated?
We run Daiken Biomedical Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 15.90 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daiken Biomedical Co., Ltd. currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daiken Biomedical Co., Ltd. (7780)?
The closing price on Nov 9, 2026 was 14.50 TWD. Our model-based fair value is 15.90 TWD, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daiken Biomedical Co., Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (11.43 TWD to 22.87 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Daiken Biomedical Co., Ltd.
How large is the market capitalisation of Daiken Biomedical Co., Ltd. (7780)?
The market capitalisation of Daiken Biomedical Co., Ltd. is 11.7B TWD (≈ $358M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daiken Biomedical Co., Ltd. (7780)?
The price-to-sales ratio of Daiken Biomedical Co., Ltd. is 25.9 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daiken Biomedical Co., Ltd. (7780)?
Earnings per share at Daiken Biomedical Co., Ltd. are 0.1000 TWD (price ÷ EPS = P/E 145.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daiken Biomedical Co., Ltd. (7780)?
The dividend yield of Daiken Biomedical Co., Ltd. is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daiken Biomedical Co., Ltd. (7780)?
The net margin of Daiken Biomedical Co., Ltd. is 17.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daiken Biomedical Co., Ltd. (7780)?
The return on equity (ROE) of Daiken Biomedical Co., Ltd. is 14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daiken Biomedical Co., Ltd. (7780)?
On an EBIT basis the return on assets of Daiken Biomedical Co., Ltd. is 15.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daiken Biomedical Co., Ltd. (7780)?
The operating margin of Daiken Biomedical Co., Ltd. is 20.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daiken Biomedical Co., Ltd. (7780)?
Revenue at Daiken Biomedical Co., Ltd. is growing +35.5% versus a year earlier (3y avg +28.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daiken Biomedical Co., Ltd. (7780)?
Earnings per share at Daiken Biomedical Co., Ltd. are growing +161% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Daiken Biomedical Co., Ltd. in the live analysis
One click puts Daiken Biomedical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026